Patents by Inventor Catherine R. L. Graves

Catherine R. L. Graves has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Tumour markers
    Patent number: 9696319
    Abstract: A method of determining the immune response of a mammal to circulating tumor marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumor marker antigen. The presence of complexes between the tumor marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumor marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient.
    Type: Grant
    Filed: January 12, 2012
    Date of Patent: July 4, 2017
    Assignee: Oncimmune Ltd.
    Inventors: John F. R. Robertson, Catherine R. L. Graves, Michael R. Price, Frances M Price
  • Tumour Markers
    Publication number: 20130090251
    Abstract: A method of determining the immune response of a mammal to circulating tumour marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumour marker antigen. The presence of complexes between the tumour marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumour marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient.
    Type: Application
    Filed: April 3, 2012
    Publication date: April 11, 2013
    Applicant: Onclmmune Limited
    Inventors: John F.R. Robertson, Catherine R.L. Graves, Frances M. Price
  • Tumour Markers
    Publication number: 20120115749
    Abstract: A method of determining the immune response of a mammal to circulating tumour marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumour marker antigen. The presence of complexes between the tumour marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumour marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient.
    Type: Application
    Filed: January 12, 2012
    Publication date: May 10, 2012
    Applicant: Onclmmune Limited
    Inventors: John F.R. Robertson, Catherine R.L. Graves, Michael R. Price, Frances Margaret Price
  • Tumour markers
    Patent number: 8114604
    Abstract: A method of determining the immune response of a mammal to circulating tumour marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumour marker antigen. The presence of complexes between the tumour marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumour marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient.
    Type: Grant
    Filed: December 10, 2007
    Date of Patent: February 14, 2012
    Assignee: OncImmune Ltd.
    Inventors: John F. R. Robertson, Catherine R. L. Graves, Michael R. Price, Frances Margaret Price, legal representative
  • Tumour markers
    Patent number: 7402403
    Abstract: A method of determining the immune response of a mammal to circulating tumour marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumour marker antigens. The presence of complexes between the tumour marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumour marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient.
    Type: Grant
    Filed: May 11, 1999
    Date of Patent: July 22, 2008
    Assignee: OncImmune Limited
    Inventors: John F. R. Robertson, Catherine R. L. Graves, Frances M. Price, legal representative, Michael R. Price
  • Tumour Markers
    Publication number: 20080153113
    Abstract: A method of determining the immune response of a mammal to circulating tumour marker proteins is described in which a sample of bodily fluid, for example plasma or serum, is contacted with a panel of two or more distinct tumour marker antigen. The presence of complexes between the tumour marker antigens and any autoantibodies to the antigens present in the sample are detected and provide an indication of an immune response to a circulating tumour marker protein. The method is useful for the diagnosis of cancer, particularly for identifying new or recurrent cancer in an otherwise assymptomatic patient.
    Type: Application
    Filed: December 10, 2007
    Publication date: June 26, 2008
    Inventors: John F.R. Robertson, Catherine R.L. Graves, Michael R. Price, Frances M. Price